Search

Savara Inc

Geschlossen

BrancheGesundheitswesen

5.27 1.54

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

5.17

Max

5.33

Schlüsselkennzahlen

By Trading Economics

Einkommen

-2.9M

-40M

EPS

-0.16

Angestellte

70

EBITDA

-3M

-40M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+109.74% upside

Dividenden

By Acuity

Nächstes Ergebnis

10. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-77M

1.1B

Vorheriger Eröffnungskurs

3.73

Vorheriger Schlusskurs

5.27

Nachrichtenstimmung

By Acuity

50%

50%

129 / 339 Ranking in Healthcare

Savara Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Sept. 2026, 20:07 UTC

Savara Inc shares are lower, impacted by a sharp decline in the NY Empire State Manufacturing Index and rising oil prices amid broader market weakness.

11. Sept. 2026, 20:08 UTC

Savara Inc. shares are trading lower today, continuing a decline since Thursday's close amid a broader market downturn.

10. Sept. 2026, 20:03 UTC

Savara Inc. shares are lower today, reflecting broader market conditions amid the European Central Bank's recent interest rate hike and inflation projections.

4. Sept. 2026, 19:26 UTC

Savara Inc shares are higher today, trading within a narrow range. The stock is currently near the lower end of its one-month range.

3. Sept. 2026, 20:02 UTC

Savara Inc shares are lower during Thursday's session, retracing from an earlier peak amid rising jobless claims that may affect Federal Reserve policy.

2. Sept. 2026, 20:08 UTC

Savara Inc. shares are higher today, driven by a significant upward trend in the Biotechnology sub-sector. No specific company news was identified.

1. Sept. 2026, 19:36 UTC

Savara Inc. shares are lower today, continuing a decline since Monday. The stock remains below its 20-day moving average amid rising inflation concerns.

31. Aug. 2026, 22:01 UTC

Savara Inc. shares rose in after-market trading, advancing since Monday's close, despite earlier pulling back from a session high. No specific news was identified.

28. Aug. 2026, 21:02 UTC

In after-market trading, Savara Inc. has increased following a flat start, indicating upward momentum despite remaining below its 20-day moving average.

27. Aug. 2026, 23:56 UTC

Savara Inc shares are higher in after-market trading, despite no specific news. Broader market sentiment remains mixed amid ongoing inflation concerns and upcoming Fed guidance.

25. Aug. 2026, 19:16 UTC

Event

Savara Inc announced presentations at the ERS Congress, yet shares are trading lower today, reflecting a slight decline since Monday's close.

24. Aug. 2026, 22:01 UTC

News

Savara Inc. will present Phase 3 trial results for molgramostim at the European Respiratory Society Congress in 2026. Shares are higher in after-market trading.

21. Aug. 2026, 19:36 UTC

News

Savara Inc. granted inducement awards to eight new employees, including options for 74,500 shares. Shares are higher since Thursday's close.

20. Aug. 2026, 20:02 UTC

Savara Inc shares are lower amid a broader market downturn, influenced by disappointing sales growth from major retailers like Walmart Inc. Trading volume remains unusually high.

19. Aug. 2026, 19:26 UTC

Savara Inc is trading higher today, maintaining upward momentum since Tuesday's close. The stock moved from a session low to a pre-market high.

18. Aug. 2026, 23:01 UTC

Savara Inc shares declined in after-market trading, falling below their 20-day moving average after an earlier surge. No specific news was identified to explain the volatility.

17. Aug. 2026, 19:46 UTC

Savara Inc is trading lower today, retracing from earlier gains and near the lower end of its one-month range. No specific news was identified.

14. Aug. 2026, 19:44 UTC

Savara Inc shares are higher today amid increased trading volume. No specific company news was identified to explain the price movement.

13. Aug. 2026, 20:02 UTC

Savara Inc shares are lower today, continuing a decline since Wednesday. The stock saw high trading volume amid no specific news.

12. Aug. 2026, 19:56 UTC

News

Savara Inc. shares are higher following Citizens' reaffirmation of its Outperform rating and $10 price target ahead of the MOLBREEVI PDUFA date.

11. Aug. 2026, 19:11 UTC

Savara Inc shares are lower today amid unusually high market volume. No specific news was identified to explain the decline.

10. Aug. 2026, 23:01 UTC

Savara Inc shares are lower in after-market trading, showing notable volatility without any specific news to explain the decline.

7. Aug. 2026, 19:36 UTC

Savara Inc is trading higher, benefiting from broader market gains following a weaker-than-expected jobs report that may delay Federal Reserve interest rate hikes.

6. Aug. 2026, 20:06 UTC

Savara Inc shares are higher today, recovering from earlier declines and trading above their 20-day moving average. No specific news was identified for the move.

5. Aug. 2026, 19:36 UTC

News

Savara Inc. shares are higher as the company advances its Biologics License Application for molgramostim, with a key PDUFA date approaching.

4. Aug. 2026, 23:01 UTC

Savara Inc shares are trading higher in after-market hours, showing significant volatility with no specific news identified to explain the price movement.

3. Aug. 2026, 20:06 UTC

Savara Inc is declining today, diverging from recent higher closes. Broader market indices, including the S&P 500 and Nasdaq 100, are gaining.

31. Juli 2026, 20:06 UTC

Event

Savara Inc shares are lower despite the European Patent Office granting a patent for MOLBREEVI, effective through March 2041. The stock remains near its one-month low.

30. Juli 2026, 20:09 UTC

Event

Savara Inc shares rise after the European Patent Office grants a patent for MOLBREEVI, providing protection until March 2041.

29. Juli 2026, 19:47 UTC

Savara Inc's shares are lower, marking five consecutive sessions of decline. Broader market performance is mixed as traders await the Federal Reserve's interest rate decision.

Peer-Vergleich

Kursveränderung

Savara Inc Prognose

Kursziel

By TipRanks

109.74% Vorteil

12-Monats-Prognose

Durchschnitt 11.2 USD  109.74%

Hoch 16 USD

Tief 9 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Savara Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

5

Buy

0

Halten

0

Sell

Stimmung

By Acuity

129 / 339 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat